Maximizing reproductive fertility options is just as important as beating cancer, primarily bridging the gap for patient education and fertility resources. Join Dr. Jennifer MacDonald as she interviews Drs. Scott Richard and Rachel Danis, addressing premature ovarian failure, ovarian preservation, and how chemo agents, radiation, and surgery can affect the patient’s natural fertility options.
 
2024-2025 SGO Chemotherapy and Immunotherapy Subcommittee Lead and Moderator:
Jennifer MacDonald, PharmD, BCOP
 
Speakers: 
Scott Richard, MD 
Rachel Blair Danis, MD, MS
 
 

Listen to Dr. Jennifer MacDonald interview Drs. Scott Richard and Rachel Danis, discussing the importance of fertility preservation for cancer patients, partnering with a reproductive endocrinology and infertility clinic (REI) to expand fertility options for future family building, and patients utilizing grant/nonprofit funding resources to financially assist with fertility treatment options.

2024-2025 SGO Chemotherapy Immunotherapy Subcommittee Lead and Moderator:
Jennifer MacDonald, PharmD, BCOP
 
Speakers: 
Scott Richard, MD 
Rachel Blair Danis, MD, MS 

Potential Funding Resources: 

1. Livestrong is a nonprofit organization that helps people affected by cancer with resources, programs, and advocacy.
   
   
2. The Chick Mission idea "hatched" when Amanda's fertility preservation coverage was denied by her insurance company. Staring down a long road of chemo, radiation and long-term drug therapy, Amanda understood the high likelihood of infertility after her treatment and decided to move forward covering the costs on her own. The idea of other patients choosing not to pursue preservation simply because of the cost barrier did not sit well - socioeconomic standing should not dictate whether anyone has an opportunity to have biological children after they battle and beat cancer.

This is the last of the three-part podcast series, Keeping up with the Chemos on CDK 4/6 inhibitors. Our multidisciplinary panel will discuss the challenges with patient monitoring while on CDK 4/6 inhibitors. When to dose adjust and hold or even discontinue CDK 4/6 inhibitors. Once again, the podcast ends with take home points for patient monitoring, medication management, and side effects while on CDK 4/6 inhibitors.  

2024-2025 SGO Chemotherapy and Immunology Subcommittee Lead and Moderator:
Jennifer MacDonald, PharmD, BCOP
 
Speakers: 
Julia Fehniger, MD
Jodi L. Taraba, PharmD, MS, RPh, BCOP
Siddhartha Yadav, M.B.B.S, MD

This is the second of the three-part podcast series, Keeping up with the Chemos on CDK 4/6 inhibitors. Our multidisciplinary panel will discuss the important information about the drug preparation and administration of CDK 4/6 inhibitors.  Focusing on dosing, supportive care, and patient education. The session ends with general take home points on administration and toxicity prevention interventions.

2024-2025 SGO Chemotherapy and Immunology Subcommittee Lead and Moderator:
Jennifer MacDonald, PharmD, BCOP
 
Speakers: 
Julia Fehniger, MD
Jodi L. Taraba, PharmD, MS, RPh, BCOP
Siddhartha Yadav, M.B.B.S, MD

This is the first of the three-part podcast series, Keeping up with the Chemos on CDK 4/6 inhibitors. After going over some general information on CDK 4/6 inhibitors including when to use the drug, toxicity, response rates, repeat biopsy, and line of therapy and treatment option. The multidisciplinary panel will discuss dosing and drug preparation for giving CDK 4/6 inhibitors. The session wraps up with some key take home points on CDK 4/6 inhibitors.

2024-2025 SGO Chemotherapy and Immunology Subcommittee Lead and Moderator:
Jennifer MacDonald, PharmD, BCOP
 
Speakers: 
Julia Fehniger, MD
Jodi L. Taraba, PharmD, MS, RPh, BCOP
Siddhartha Yadav, M.B.B.S, MD

Let’s do this -- This podcast features patient advocates who share their experiences and offer valuable insights from their journeys as cervical cancer patients and survivors. It is hosted by the Health Equity Subcommittee, a division of the SGO Diversity, Inclusion, and Health Equity (DIHE) Committee.

Moderators:

• Lindsay Kuroki, MD, MSCI, Washington University Physicians, DIHE Health Equity subcommittee Chair
• Nancy Zhou, MD, Rutgers Health - NJMS, DIHE Health Equity subcommittee Member

 Speakers:

• Mindy Dunn, Cancer Survivor
• Linda Ryan, Cancer Survivor and Patient Advocate 

Resource Links:
Foundation for Women's Cancer (FWC) Cervical Cancer: Your Guide 

This is the last of the three-part podcast series, Keeping up with the Chemos on Trastuzumab Deruxtecan ENHERTU®. Our multidisciplinary panel will discuss the challenges with patient monitoring while on Trastuzumab Deruxtecan ENHERTU®. When to dose adjust and hold or even discontinue Trastuzumab Deruxtecan ENHERTU®. Once again, the podcast ends with take home points for patient monitoring and side effects while on Trastuzumab Deruxtecan ENHERTU®.  

2023-2024 SGO Chemotherapy and Targeted Therapies Subcommittee Member and Moderator:
Tracilyn Hall, MD

Speakers:
Jennifer MacDonald, PharmD, BCOP
Kathleen Moore, MD
Bernard Tawfik, MD 

In honor of Endometrial Cancer Awareness Month, we encourage you to read the latest HER2 Molecular Card and Trastuzumab Deruxtecan ENHERTU® Chemotherapy Card available now on SGO ConnectEd.

HER2 Molecular Card: https://connected.sgo.org/content/molecular-target-human-epidermal-growth-factor-receptor-2-her2

Trastuzumab Deruxtecan ENHERTU® Chemotherapy Card: https://connected.sgo.org/content/chemotherapy-targeted-therapies-flash-cards

This is the second of the three-part podcast series, Keeping up with the Chemos on Trastuzumab Deruxtecan ENHERTU®.  Our multidisciplinary panel will discuss the important information about the drug preparation and administration of Trastuzumab Deruxtecan ENHERTU®.  Focusing on dosing, breast scoring, HER2, infusion reactions, lab examinations, and patient education. The session ends with general take home points on administration and toxicity prevention interventions.

2023-2024 SGO Chemotherapy and Targeted Therapies Subcommittee Member and Moderator:
Tracilyn Hall, MD

Speakers:
Jennifer MacDonald, PharmD, BCOP
Kathleen Moore, MD
Bernard Tawfik, MD 

In honor of Endometrial Cancer Awareness Month, we encourage you to read the latest HER2 Molecular Card and Trastuzumab Deruxtecan ENHERTU® Chemotherapy Card available now on SGO ConnectEd.

HER2 Molecular Card: https://connected.sgo.org/content/molecular-target-human-epidermal-growth-factor-receptor-2-her2

Trastuzumab Deruxtecan ENHERTU® Chemotherapy Card: https://connected.sgo.org/content/chemotherapy-targeted-therapies-flash-cards

This is the first of the three-part podcast series, Keeping up with the Chemos on Trastuzumab Deruxtecan ENHERTU®. After going over some general information on Trastuzumab Deruxtecan ENHERTU® including when to use the drug, checking patient performance status, toxicity, response rates in breast, and line of therapy and treatment option. The multidisciplinary panel will discuss dosing and drug preparation for giving Trastuzumab Deruxtecan ENHERTU®. The session wraps up with some key take home points on Trastuzumab Deruxtecan ENHERTU®. 

2023-2024 SGO Chemotherapy and Targeted Therapies Subcommittee Member and Moderator:
Tracilyn Hall, MD

Speakers:
Jennifer MacDonald, PharmD, BCOP
Kathleen Moore, MD
Bernard Tawfik, MD 

In honor of Endometrial Cancer Awareness Month, we encourage you to read the latest HER2 Molecular Card and Trastuzumab Deruxtecan ENHERTU® Chemotherapy Card available now on SGO ConnectEd.

HER2 Molecular Card: https://connected.sgo.org/content/molecular-target-human-epidermal-growth-factor-receptor-2-her2

Trastuzumab Deruxtecan ENHERTU® Chemotherapy Card: https://connected.sgo.org/content/chemotherapy-targeted-therapies-flash-cards

In this podcast, we will focus on same day discharge as part of Enhanced Recovery after Surgery (ERAS).

Over the past two decades, and especially after the publication of the GOG LAP2 trial, minimally invasive surgery has been widely adopted in gynecologic oncology, as it is associated with lower rates of complications, and improved postoperative recovery and return to normal activity. 

Postoperative hospitalization is typically shorter after minimally invasive (MIS) hysterectomy, and many patients may even be candidates for discharge on the day of surgery, so-called same-day discharge (SDD).

2023-2024 SGO ERAS Subcommittee Members and Speakers:
Lee-may Chen, MD; Subcommittee Lead and Moderator
Nawar Latif, MD, MPH, MSCE
Clarissa Polen-De, MD
Michael Shu, MD
Collin Sitler, DO
Brenna Swift, MD, MASc, MSc, FRCSC
Diogo Torres, MD